Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05842928
Other study ID # 01VSF21038
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 25, 2023
Est. completion date December 2024

Study information

Verified date May 2023
Source Ludwig-Maximilians - University of Munich
Contact Tobias Dreischulte, Prof. Dr.
Phone +49 89 4400 55447
Email tobias.dreischulte@med.uni-muenchen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag/medication review and patient empowerment, (4) GP practice visit with shared decision making. The control intervention only comprises a pharmacy visit with brown bag review.


Recruitment information / eligibility

Status Recruiting
Enrollment 352
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Aged 65 years or older - Patient is capable of giving consent - GP contact in the quarter prior to inclusion - Current use of = 5 drugs, including = 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of = 6 months - Willingness to select a regular pharmacy for the study period - Consent to data exchange between GP and community pharmacy Exclusion Criteria: - Terminal illness (life expectancy < 6 months) - Current treatment of pain associated with cancer - Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment) - Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment) - Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity) - Current participation in research projects on medication safety or geriatric medicine

Study Design


Intervention

Behavioral:
PARTNER intervention
The PARTNER intervention includes the following components: Education for health care professionals A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations; B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions; C) checklist for identification of drug-related problems for pharmacists; D) tapering support tool to facilitate the selection of tapering schemes; E) divisibility list for PSA-PIM to support the implementation of tapering schemes; F) empowerment brochures for patients each focussing on one PSA-PIM subgroup Interprofessional workshop and case conference for GPs and pharmacists Pharmacy visit (brown bag/medication review) including patient empowerment GP practice visit including shared decision making (SDM)
Control intervention
The control intervention only comprises a pharmacy visit with brown bag review.

Locations

Country Name City State
Germany University of Bielefeld Bielefeld
Germany University Hospital, LMU Munich Munich
Germany Witten/Herdecke University Witten

Sponsors (8)

Lead Sponsor Collaborator
Ludwig-Maximilians - University of Munich Bielefeld University, Federal Joint Committee, Institute for Applied Quality Improvement and Research in Health Care, Techniker Krankenkasse, University Hospital Heidelberg, University Hospital Regensburg, University of Witten/Herdecke

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in the PSA-PIM Drug Burden Index (DBI) by = 0.15 points Clinically relevant reduction in PSA-PIM exposure at patient level after 6 months follow-up, as measured by the Drug Burden Index method. The primary endpoint is defined as a responder endpoint at patient level, where response is defined as a reduction in the Drug Burden Index (DBI) by = 0.15 points (Primary endpoint: T2 vs T0) 6 months
Secondary Reduction in the PSA-PIM Drug Burden Index (DBI) by = 0.15 points Clinically relevant reduction in PSA-PIM exposure at patient level after 12 months follow-up, as measured by the Drug Burden Index method (T4 vs T0) 12 months
Secondary Frequency of deprescribing PSA-PIM stratified by PSA-PIM subgroups Proportion (%) of patients with a reduction in DBI = 0.15 (T2 vs T0; T4 vs T0) 12 months
Secondary Total exposure with PSA-PIM Average of the Drug Burden Index (DBI); mean change in the number of PSA-PIM taken (T2 vs T0; T4 vs T0) 12 months
Secondary Total exposure to PSA-PIM stratified by PSA-PIM subgroups Average of the Drug Burden Index (DBI); mean change in the number of PSA-PIM taken (T2 vs T0; T4 vs T0) 12 months
Secondary Frequency of new PSA-PIM prescriptions Proportion (%) of patients with a new prescription of =1 PSA-PIM (T2 vs T0; T4 vs T0) 12 months
Secondary Frequency of taking other potentially inappropriate medication (PIM) (Validated PIM lists, e.g. PRISCUS list, START/STOPP, Anticholinergic Burden) Average change in the number of PIMs (T2 vs T0; T4 vs T0) 12 months
Secondary Number of falls and hospitalisations due to fall events (Falls diary, Hospitalisation diary according to FIMA) Proportion (%) of patients with falls/hospitalisations due to fall injuries (T2 vs T0; T4 vs T0) 12 months
Secondary Cognition (Verbal Fluency Test) Average (T2 vs T0; T4 vs T0) 12 months
Secondary Quality of life (EQ5-D-5L) Average (T2 vs T0; T4 vs T0) 12 months
Secondary Insomnia (Regensburg Insomnia Scale; RIS) Change from baseline in psychological symptoms and sleep assessed with the Regensburg Insomnia Scale (RIS). RIS includes 10 questions on cognitive, emotional and psychophysiological aspects of a sleep disorder. Five answer options for each question are possible (scored 0 to 4; higher scores indicate higher burden). The overall RIS score is the sum of the scores from each of the 10 questions. The overall RIS score can therefore range from zero to 40.
Average (T2 vs T0; T4 vs T0)
12 months
Secondary Adverse drug reactions (ADRs) Average (T2 vs T0; T4 vs T0) 12 months
See also
  Status Clinical Trial Phase
Completed NCT03380533 - Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair Phase 2/Phase 3
Completed NCT05004519 - Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass N/A
Not yet recruiting NCT04836169 - Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy N/A
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Active, not recruiting NCT03366805 - A Patient Education Video Program for Post-Operative Recovery After Upper Extremity Surgery N/A
Recruiting NCT04144933 - Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery Phase 3
Completed NCT04369950 - Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine Phase 4
Active, not recruiting NCT03485430 - Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up N/A
Completed NCT05099055 - Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study Phase 3
Completed NCT03858621 - Comparison of Postoperative Nociception Between NOL-guided and Standard Intraoperative Analgesia Based on Fentanyl N/A
Recruiting NCT06390046 - Opioid-free Anesthesia, Optimization of Anesthesia After Bariatric Surgery N/A
Recruiting NCT06380244 - Opioid-free Anesthesia as an Alternative to General Anesthesia in Abdominal Surgery N/A
Completed NCT03991546 - Pain and Narcotic Usage After Orthopaedic Surgery N/A
Withdrawn NCT02985177 - A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture Phase 4
Completed NCT05581901 - Perioperative Methadone in Hip Fracture Patients Phase 4
Withdrawn NCT04397458 - Rescue Quadratus Lumborum Blocks for Post-cesarean Pain Phase 4
Completed NCT03294109 - Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy Phase 4
Completed NCT04204967 - Totally Transdermal Sedation in the Weaning From Remifentanil Infusion Phase 2
Completed NCT02665429 - A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department N/A
Completed NCT04355468 - Opioid Free Anesthesia in Thoracic Surgery N/A